• Completed

NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study

Updated: Mar 28

GEN501 study

GEN501 STUDY DARA

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma


Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.


Multiple Locations

International Study


ClinicalTrials.gov Identifier: NCT00574288


Official Title: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

 

Publications:


Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.

Lancet Haematol. 2020 Jun;7


Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

N Engl J Med. 2015 Sep 24


Posts Archive